-
1
-
-
67649537590
-
An evidence-based systematic review on the management of irritable bowel syndrome
-
Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.
-
(2009)
Am J Gastroenterol
, vol.104
, Issue.SUPPL. 1
-
-
Brandt, L.J.1
Chey, W.D.2
Foxx-Orenstein, A.E.3
-
2
-
-
84856828482
-
Diarrhea, constipation, and irritable bowel syndrome
-
DiPiro J T, Talbert RL, Yee GC, et al, 8th ed. New York, NY: McGraw Hill, Accessed December 3, 2011
-
Powell PH, Fleming VH. Diarrhea, constipation, and irritable bowel syndrome. In: DiPiro J T, Talbert RL, Yee GC, et al. Pharmacother-apy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw Hill; 2011. Available at http://www.accesspharmacy.com/content.aspx?aID=7978775. Accessed December 3, 2011.
-
(2011)
Pharmacother-apy: A Pathophysiologic Approach
-
-
Powell, P.H.1
Fleming, V.H.2
-
3
-
-
0141653832
-
Chronic constipation
-
Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349(14):1360-1368.
-
(2003)
N Engl J Med
, vol.349
, Issue.14
, pp. 1360-1368
-
-
Lembo, A.1
Camilleri, M.2
-
4
-
-
0034464011
-
American Gastroenterological Association medical position statement: Guidelines on constipation
-
Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1766.
-
(2000)
Gastroenterology
, vol.119
, pp. 1761-1766
-
-
Locke, G.R.1
Pemberton, J.H.2
Phillips, S.F.3
-
5
-
-
78650743393
-
Lubiprostone: Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome
-
Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health. 2010;2:361-374.
-
(2010)
Int J Womens Health
, vol.2
, pp. 361-374
-
-
Lunsford, T.N.1
Harris, L.A.2
-
6
-
-
77449106445
-
Methylnaltrexone: A subcutaneous treatment for opioid-induced constipation in palliative care patients
-
Kyle G. Methylnaltrexone: a subcutaneous treatment for opioid-induced constipation in palliative care patients. Int J Palliat Nurs. 2009;15(11):533-540.
-
(2009)
Int J Palliat Nurs
, vol.15
, Issue.11
, pp. 533-540
-
-
Kyle, G.1
-
7
-
-
0036792345
-
Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome
-
Tougas G, Snape WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(10):1701-1708.
-
(2002)
Aliment Pharmacol Ther
, vol.16
, Issue.10
, pp. 1701-1708
-
-
Tougas, G.1
Snape, W.J.2
Otten, M.H.3
-
8
-
-
79959789162
-
-
FDA, Accessed December 3, 2011
-
FDA. Public health advisory: tegaserod ma-leate (marketed as Zelnorm); March 30, 2007. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor-mationforPatientsandProviders/DrugSafe-tyInformationforHealthcareProfessionals/ PublicHealthAdvisories/ucm051284.htm. Accessed December 3, 2011.
-
(2007)
Public Health Advisory: Tegaserod Ma-leate (marketed As Zelnorm)
-
-
-
9
-
-
41949139816
-
-
FDA, press release, Accessed December 3, 2011
-
FDA. FDA permits restricted use of Zelnorm for qualifying patients [press release]; July 27, 2007. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/2007/ucm108956.htm. Accessed December 3, 2011.
-
(2007)
FDA Permits Restricted Use of Zelnorm For Qualifying Patients
-
-
-
11
-
-
84856833434
-
-
Amitiza [prescribing information]. Bethesda, MD: Sucampo Pharma Americas, Inc
-
Amitiza [prescribing information]. Bethesda, MD: Sucampo Pharma Americas, Inc, 2011.
-
(2011)
-
-
-
13
-
-
78049283798
-
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit
-
Busby RW, Bryant A P, Bartolini W P, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649:328-335.
-
(2010)
Eur J Pharmacol
, vol.649
, pp. 328-335
-
-
Busby, R.W.1
Bryant, A.P.2
Bartolini, W.P.3
-
14
-
-
77951897011
-
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
-
Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86:760-765.
-
(2010)
Life Sci
, vol.86
, pp. 760-765
-
-
Bryant, A.P.1
Busby, R.W.2
Bartolini, W.P.3
-
15
-
-
71649115806
-
Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis [abstract 486]
-
Ustinova E, Bryant A, Rez T, et al. Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis [abstract 486]. Am J Gas-troenterol. 2008(suppl 1);103:S187.
-
(2008)
Am J Gas-troenterol
, vol.103
, Issue.SUPPL. 1
-
-
Ustinova, E.1
Bryant, A.2
Rez, T.3
-
16
-
-
83155177478
-
Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation [abstract 292]
-
Kessler MM, Busby RW, Wakefleld JD, et al. Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation [abstract 292]. Drug Metab Rev. 2008;40(suppl 3):213-214.
-
(2008)
Drug Metab Rev
, vol.40
, Issue.SUPPL. 3
, pp. 213-214
-
-
Kessler, M.M.1
Busby, R.W.2
Wakefleld, J.D.3
-
17
-
-
83155182931
-
Linaclotide: A novel approach to the treatment of irritable bowel syndrome
-
Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann Pharmacother. 2011 Dec;45(12):1535-1543.
-
(2011)
Ann Pharmacother
, vol.45
, Issue.12
, pp. 1535-1543
-
-
Wensel, T.M.1
Luthin, D.R.2
-
18
-
-
83155185785
-
Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: Results from a randomized, double-blind, placebo-controlled phase 3 trial [AGA abstract 837]
-
Chey WD, Lembo A, MacDougall JE, et al. Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial [AGA abstract 837]. Gastroenterology. 2011(suppl);140:S135.
-
(2011)
Gastroenterology
, vol.140
, Issue.SUPPL.
-
-
Chey, W.D.1
Lembo, A.2
Macdougall, J.E.3
-
19
-
-
82955175836
-
Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: A 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period [AGA abstract 845]
-
Rao S, Lembo A, Shiff SJ, et al. Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period [AGA abstract 845]. Gastroenterology. 2011(suppl):140:S138.
-
(2011)
Gastroenterology
, vol.140
, Issue.SUPPL.
-
-
Rao, S.1
Lembo, A.2
Shiff, S.J.3
-
20
-
-
80051640525
-
Two randomized trials of linaclotide for chronic constipation
-
Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527-536.
-
(2011)
N Engl J Med
, vol.365
, pp. 527-536
-
-
Lembo, A.J.1
Schneier, H.A.2
Shiff, S.J.3
-
21
-
-
83155177485
-
Effect of linaclotide on quality of life in adults wih irritable bowel syndrome with constipation: Pooled results from two randomized, double-blind, placebo-controlled phase 3 trials [AGA abstract 223]
-
Carson R, Tourkodimitris S, Lewis BE, et al. Effect of linaclotide on quality of life in adults wih irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials [AGA abstract 223]. Gastroenterology. 2011(suppl);140:S51.
-
(2011)
Gastroenterology
, vol.140
, Issue.SUPPL.
-
-
Carson, R.1
Tourkodimitris, S.2
Lewis, B.E.3
-
22
-
-
84856828479
-
-
[AGA poster session abstract Sa1007]. Digestive Disease Week 2011, Chicago, Illinois
-
Carson R, Tourkodimitris S, Lewis BE, Johnston JM. Effect of linaclotide on quality of life among patients with chronic constipation (CC) with abdominal symptoms [AGA poster session abstract Sa1007]. Digestive Disease Week 2011, Chicago, Illinois, May 7, 2011.
-
Effect of Linaclotide On Quality of Life Among Patients With Chronic Constipation (CC) With Abdominal Symptoms
, pp. 2011
-
-
Carson, R.1
Tourkodimitris, S.2
Lewis, B.E.3
Johnston, J.M.4
-
23
-
-
77249122338
-
Efficacy of linaclotide for patients with chronic constipation
-
Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886-895.
-
(2010)
Gastroenterology
, vol.138
, pp. 886-895
-
-
Lembo, A.J.1
Kurtz, C.B.2
Macdougall, J.E.3
-
24
-
-
60749099506
-
Pilot study on the effect of linaclotide in patients with chronic constipation
-
Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gas-troenterol. 2009;104:125-132.
-
(2009)
Am J Gas-troenterol
, vol.104
, pp. 125-132
-
-
Johnston, J.M.1
Kurtz, C.B.2
Drossman, D.A.3
-
25
-
-
78649690668
-
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation
-
Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877-1886.
-
(2010)
Gastroenterology
, vol.139
, pp. 1877-1886
-
-
Johnston, J.M.1
Kurtz, C.B.2
Macdougall, J.E.3
-
26
-
-
77956258377
-
Effect of linaclotide on IBS-C symptoms in the flrst week of treatment: Results from a phase 2B study [AGA abstract 157]
-
Lembo AJ, Johnston JM, Lavins BJ, et al. Effect of linaclotide on IBS-C symptoms in the flrst week of treatment: results from a phase 2B study [AGA abstract 157]. Gastroenterology. 2009(suppl);136:A30-A31.
-
(2009)
Gastroenterology
, vol.136
, Issue.SUPPL.
-
-
Lembo, A.J.1
Johnston, J.M.2
Lavins, B.J.3
-
27
-
-
79953307643
-
Global end points in IBS clinical trials: Results from a phase 2B study of linaclotide [AGA abstract 236]
-
Johnston JM, MacDougall JE, Lavins BJ, et al. Global end points in IBS clinical trials: results from a phase 2B study of linaclotide [AGA abstract 236]. Gastroenterology. 2009 (suppl);136:A45-A46.
-
(2009)
Gastroenterology
, vol.136
, Issue.SUPPL.
-
-
Johnston, J.M.1
Macdougall, J.E.2
Lavins, B.J.3
|